Skip to content
20-F

Annual Report (Foreign)

Altamira Therapeutics Ltd. CYTOF

0001213900-25-037199

← back to feed
Filed
Apr 30, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2024 · Dec 31, 2024 2.83M sh
Shares Outstanding FY 2024 · Dec 31, 2024 4.66M sh
Operating Cash Flow FY 2024 · Dec 31, 2024 −$6.11M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$12.81M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$9.09M
Cash And Equivalents FY 2024 · Dec 31, 2024 $998.62K
Cash And Equivalents FY 2024 · Dec 31, 2023 $733.7K
Cash And Equivalents FY 2024 · Jan 1, 2023 $16.64K
Cash And Equivalents FY 2024 · Dec 31, 2022 $16.64K
Cash And Equivalents FY 2024 · Dec 31, 2021 $1.08M
Current Liabilities FY 2024 · Dec 31, 2024 $1.16M
Current Liabilities FY 2024 · Dec 31, 2023 $1.06M
Current Liabilities FY 2024 · Jan 1, 2023 $13.92M
Current Assets FY 2024 · Dec 31, 2024 $1.54M
Current Assets FY 2024 · Dec 31, 2023 $1.45M
Current Assets FY 2024 · Jan 1, 2023 $1.91M
Total Assets FY 2024 · Dec 31, 2024 $8.65M
Total Assets FY 2024 · Dec 31, 2023 $9.14M
Total Assets FY 2024 · Jan 1, 2023 $6.81M
Eps Diluted FY 2024 · Dec 31, 2024 −$2.99
Eps Diluted FY 2024 · Dec 31, 2023 −$8.77
Eps Diluted FY 2024 · Dec 31, 2022 −$610.03
Eps Basic FY 2024 · Dec 31, 2024 −$2.99
Eps Basic FY 2024 · Dec 31, 2023 −$8.77
Eps Basic FY 2024 · Dec 31, 2022 −$610.03
Operating Income FY 2024 · Dec 31, 2024 −$6.85M
Operating Income FY 2024 · Dec 31, 2023 −$6.58M
Operating Income FY 2024 · Dec 31, 2022 −$18.86M